AdAlta Ltd (ASX: 1AD) MD Tim Oldham talks about 2024 plans and catalysts for fibrotic disease study

AdAlta Ltd (ASX: 1AD) MD Tim Oldham tells JustStocks the priority for the company is realising a return on the investment for AD-214 for treating fibrotic diseases. He says the company is closing in on the results of a phase 1 extension study to test the safety and tolerability of the drug in the doses that will be used in a phase 2 study. Those results are due at the end of February. Oldham also discusses how 1AD’s enterprise value sits within its peer group.

Articles of Interest